G. Michael Landis - 29 Jan 2026 Form 3 Insider Report for Polaryx Therapeutics, Inc. (PLYX)

Role
Chief Financial Officer, Director
Signature
/s/ G. Michael Landis
Issuer symbol
PLYX
Transactions as of
29 Jan 2026
Net transactions value
$0
Form type
3
Filing time
29 Jan 2026, 16:43:35 UTC
Next filing
20 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Landis G. Michael Chief Financial Officer, Director SOUTH TOWER, 140 E RIDGEWOOD AVENUE,, SUITE 415, PARAMUS /s/ G. Michael Landis 29 Jan 2026 0001548560

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PLYX Common Stock 225,358 29 Jan 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (i) 49,500 restricted stock units ("RSUs"), which will vest in two equal installments on November 1, 2026 and November 1, 2027 and (ii) 150,000 RSUs, which will vest in four equal installments on September 1, 2026, September 1, 2027, September 1, 2028 and September 1, 2029, in each case subject to the Reporting Person's continued service to the Issuer or its subsidiaries, Mstone Partners Healthcare Limited or its affiliates, or Curestone Partners Platform Limited or its affiliates. The RSUs are not deliverable unless and until the Issuer consummates a change in control within seven years of the grant date of such RSUs.

Remarks:

Exhibit 24 - Power of Attorney